

# Ken Iseri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5559021/publications.pdf>

Version: 2024-02-01

25  
papers

422  
citations

759055

12  
h-index

752573

20  
g-index

25  
all docs

25  
docs citations

25  
times ranked

646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. Journal of Bone and Mineral Metabolism, 2021, 39, 260-269.	1.3	6
2	Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. Bone, 2021, 147, 115909.	1.4	4
3	Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREATinine Measurement project. Nephrology Dialysis Transplantation, 2020, 35, 1908-1915.	0.4	14
4	Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. Bone, 2020, 130, 115075.	1.4	20
5	Bone mineral density and mortality in end-stage renal disease patients. CKJ: Clinical Kidney Journal, 2020, 13, 307-321.	1.4	36
6	Incidence of Fractures Before and After Dialysis Initiation. Journal of Bone and Mineral Research, 2020, 35, 2372-2380.	3.1	8
7	Fractures after kidney transplantation: Incidence, predictors, and association with mortality. Bone, 2020, 140, 115554.	1.4	18
8	P1409HIP FRACTURE TRENDS IN SWEDISH GENERAL POPULATION AND DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
9	P1389MAJOR OSTEOPOROTIC FRACTURES AFTER INITIATION OF DIALYSIS: INCIDENCE, PREDICTORS AND ASSOCIATION WITH MORTALITY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
10	P0673INVERSE ASSOCIATION OF TRANSFERRIN SATURATION WITH MORTALITY RISK IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
11	Therapeutic Potential of Thrombomodulin in Renal Fibrosis of Nephrotoxic Serum Nephritis in Wistar-Kyoto Rats. Kidney and Blood Pressure Research, 2020, 45, 391-406.	0.9	3
12	Major fractures after initiation of dialysis: Incidence, predictors and association with mortality. Bone, 2020, 133, 115242.	1.4	16
13	Elimination of intravenous alendronate by hemodialysis: A kinetic study. Hemodialysis International, 2019, 23, 466-471.	0.4	3
14	FP391FRACTURE RISK IN NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (CKD): INCIDENCE, PREDICTORS AND SEQUELAE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	2
15	Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis. PLoS ONE, 2019, 14, e0224690.	1.1	10
16	Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial. Journal of Bone and Mineral Research, 2019, 34, 1014-1024.	3.1	62
17	Recombinant human soluble thrombomodulin attenuates anti-glomerular basement membrane glomerulonephritis in Wistar-Kyoto rats through anti-inflammatory effects. Nephrology Dialysis Transplantation, 2019, 34, 774-782.	0.4	8
18	Highly sensitive determination of alendronate in human plasma and dialysate using metal-free HPLC-MS/MS. Legal Medicine, 2018, 30, 14-20.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 598-606.	0.4	12
20	Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. <i>PLoS ONE</i> , 2018, 13, e0206865.	1.1	46
21	The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. <i>PLoS ONE</i> , 2018, 13, e0193846.	1.1	34
22	Rituximab for the treatment of type B insulin resistance syndrome: a case report and review of the literature. <i>Diabetic Medicine</i> , 2017, 34, 1788-1791.	1.2	13
23	Therapeutic effects and mechanism of conditioned media from human mesenchymal stem cells on anti-GBM glomerulonephritis in WKY rats. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F1182-F1191.	1.3	15
24	Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy. <i>PLoS ONE</i> , 2016, 11, e0158154.	1.1	49
25	Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats. <i>PLoS ONE</i> , 2014, 9, e111728.	1.1	28